Specifically, in the presence of such mutations, treatment with a selective EGFR TKI is associated with superior progression-free survival (PFS), increased overall response rate (ORR), a more favorable toxicity profile, and an improved quality of life with respect to cytotoxic chemotherapy [1,6,10,11].
The improved CR rates have translated into superior progression-free survival and OS [ 12].
The primary endpoint of the study was not met: sunitinib and mFOLFOX6 failed to demonstrate superior progression-free survival compared with bevacizumab and mFOLFOX6.
By univariate analysis, intensive treatment and a low PI were associated with a superior progression-free survival (PFS); only PI was associated with overall survival.
The BMF schedule demonstrated superior progression-free survival in first-line MBC (8.2 vs 6.7 months for CMF; Von Minckwitz et al, 2005).
Number of lines of therapy (one or two vs. more than two lines of therapy) prior to transplant, absolute lymphocyte count (absolute lymphocyte count 3000/cmm or less at diagnosis, were important predictors of superior progression-free survival (Table 3).
However, recent data indicate that patients with partial platinum-sensitive disease benefit from the combination of trabectedin and PLD compared with PLD alone, with superior progression-free survival and overall survival for the combination.
Patients with non-small cell lung cancer (NSCLC) with EGFR mutation showed superior progression-free survival by first-line tyrosine kinase inhibitor (TKI) treatment than by traditional platinum-doublet chemotherapy in several clinical trials [1]– [4].
Recently, a superior progression-free survival (PFS) with gefitinib compared with the combination of carboplatin and paclitaxel in untreated NSCLC patients with predictors of gefitinib sensitivity was proven in two large phase III studies [ 9, 10].
A randomised phase III study comparing Gef with standard carboplatin plus paclitaxel has demonstrated that Gef conferred significantly superior progression-free survival as first-line chemotherapy in patients with EGFR mutation (Mok et al, 2009).
